Table 4.
Univariable and multivariable logistic regression analyses investigating factors predictive of functional and anatomical responses
| Variables | Univariable | Multivariable | ||||
| B | 95% CI | P value | B | 95% CI | P value | |
| ≥5 ETDRS letters improvement | ||||||
| Baseline BCVA (ETDRS letters) |
−0.041 | −0.066 to 0.016 | 0.001 | −0.032 | −0.063 to 0.001 | 0.042 |
| Baseline CMT (μm) |
0.003 | 0.0003 to 0.005 | 0.030 | −0.0004 | −0.003 to 0.004 | 0.819 |
| No of Injections | 0.148 | −0.012 to 0.310 | 0.071 | 0.086 | −0.095 to 0.267 | 0.352 |
| nAMD vs DMO (DMO=ref) | 1.223 | 0.329 to 2.117 | 0.007 | 0.647 | −0.428 to 1.724 | 0.238 |
| RVO vs DMO (DMO=ref) |
1.581 | 0.540 to 2.622 | 0.003 | 1.189 | 0.067 to 2.311 | 0.038 |
| nAMD vs RVO (RVO=ref) |
−0.357 | −1.325 to 0.609 | 0.469 | −0.542 | −1.669 to 0.585 | 0.346 |
| Lens status (phakic=ref) |
−0.684 | −1.430 to 0.061 | 0.072 | – | – | – |
| Laterality of eye (right=ref) | −0.594 | −1.330 to 0.1422 | 0.114 | – | – | – |
| Age (years) | 0.027 | −0.009 to 0.063 | 0.140 | 0.019 | −0.025 to 0.064 | 0.396 |
| Smoker (yes=ref) | 0.121 | −0.625 to 0.867 | 0.750 | – | – | – |
| Hypertension (yes=ref) |
0.211 | −0.637 to 1.061 | 0.625 | – | – | – |
| Hyperlipidaemia (yes=ref) |
0.562 | −0.195 to 1.320 | 0.146 | – | – | – |
| Sex (male=ref) | 0.289 | −0.441 to 1.019 | 0.438 | – | – | – |
| ≥15 ETDRS letters improvement | ||||||
| Baseline BCVA (ETDRS letters) |
−0.054 | −0.081 to 0.028 | <0.001 | −0.065 | −0.101 to 0.029 | <0.001 |
| Baseline CMT (μm) |
0.002 | −0.0001 to 0.005 | 0.041 | −0.002 | −0.006 to 0.001 | 0.235 |
| No of Injections | 0.798 | −0.098 to 0.258 | 0.381 | 0.013 | −0.205 to 0.232 | 0.903 |
| nAMD vs DMO (DMO=ref)* | 2.108 | 0.564 to 3.652 | 0.007 | 1.673 | −0.102 to 3.450 | 0.065 |
| RVO vs DMO (DMO=ref)* |
2.593 | 0.996 to 4.191 | 0.001 | 2.562 | 0.818 to 4.305 | 0.004 |
| nAMD vs RVO (RVO=ref)* |
−0.485 | −1.420 to 0.449 | 0.309 | −0.888 | −2.111 to 0.334 | 0.154 |
| Lens status (phakic=ref) | −0.555 | −1.419 to 0.309 | 0.208 | – | – | – |
| Laterality of eye (right=ref) | −0.465 | −1.294 to 0.364 | 0.272 | – | – | – |
| Age (years) | 0.015 | −0.025 to 0.056 | 0.453 | −0.003 | −0.057 to 0.050 | 0.899 |
| Smoker (yes=ref) | 0.148 | −0.686 to 0.983 | 0.720 | – | – | – |
| Hypertension (yes=ref) |
0.073 | −0.869 to 1.016 | 0.878 | – | – | – |
| Hyperlipidaemia (yes=ref) |
0.688 | −0.143 to 1.521 | 0.105 | – | – | – |
| Sex (male=ref) | −0.075 | −0.897 to 0.746 | 0.858 | – | – | – |
| ≥10% CMT reduction | ||||||
| Baseline BCVA (ETDRS letters) |
−0.025 | −0.049 to 0.002 | 0.029 | 0.013 | −0.023 to 0.050 | 0.482 |
| Baseline CMT (μm) |
0.016 | 0.009 to 0.023 | <0.001 | 0.017 | 0.009, 0.026 | <0.001 |
| No of Injections | −0.010 | −0.170 to 0.149 | 0.899 | −0.082 | −0.292 to 0.127 | 0.441 |
| nAMD vs DMO (DMO=ref) | −0.452 | −1.327 to 0.421 | 0.310 | −0.162 | −1.378 to 1.053 | 0.793 |
| RVO vs DMO (DMO=ref) |
0.576 | −0.505 to 1.658 | 0.297 | −0.081 | −1.454 to 1.291 | 0.908 |
| nAMD vs RVO (RVO=ref) |
−1.02 | −2.041 to 0.016 | 0.046 | −0.081 | −1.433 to 1.271 | 0.906 |
| Lens status (phakic=ref) |
0.001 | −0.760 to 0.763 | 0.997 | – | – | – |
| Laterality of eye (right=ref) | 0.100 | −0.651 to 0.852 | 0.793 | – | – | – |
| Age (years) | −0.029 | −0.067 to 0.008 | 0.132 | −0.008 | −0.060 to 0.044 | 0.766 |
| Smoker (yes=ref) | 0.296 | −0.481 to 1.075 | 0.455 | – | – | – |
| Hypertension (yes=ref) |
−0.641 | −1.494 to 0.212 | 0.141 | – | – | – |
| Hyperlipidaemia (yes=ref) |
−0.473 | −1.239 to 0.292 | 0.226 | – | – | – |
| Sex (male=ref) | −0.328 | −1.086 to 0.429 | 0.396 | – | – | – |
Significant p values are bolded.
*Firth-logistics; multivariable=adjusted for baseline BCVA, baseline CMT, injection number, age and disease type.
BCVA, best-corrected visual acuity; CMT, central macular thickness; DMO, diabetic macular oedema; ETDRS, early treatment diabetic retinopathy study; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion.